Dwayne C. Jones

Array ( [id] => 17679519 [patent_doc_number] => RE049110 [patent_country] => US [patent_kind] => E1 [patent_issue_date] => 2022-06-21 [patent_title] => Pharmaceutical formulations containing dopamine receptor ligands [patent_app_type] => reissue [patent_app_number] => 16/372031 [patent_app_country] => US [patent_app_date] => 2019-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12170 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 103 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16372031 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17903722 [patent_doc_number] => RE049233 [patent_country] => US [patent_kind] => E1 [patent_issue_date] => 2022-10-04 [patent_title] => Ionizable cationic lipid for RNA delivery [patent_app_type] => reissue [patent_app_number] => 16/351301 [patent_app_country] => US [patent_app_date] => 2019-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 10880 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16351301 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17234933 [patent_doc_number] => RE048825 [patent_country] => US [patent_kind] => E1 [patent_issue_date] => 2021-11-23 [patent_title] => 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal forms [patent_app_type] => reissue [patent_app_number] => 16/294607 [patent_app_country] => US [patent_app_date] => 2019-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 7198 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16294607 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17362141 [patent_doc_number] => RE048898 [patent_country] => US [patent_kind] => E1 [patent_issue_date] => 2022-01-25 [patent_title] => Prodrugs of 2,4-pyrimidinediamine compounds and their uses [patent_app_type] => reissue [patent_app_number] => 16/291992 [patent_app_country] => US [patent_app_date] => 2019-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 33630 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16291992 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16427602 [patent_doc_number] => RE048301 [patent_country] => US [patent_kind] => E1 [patent_issue_date] => 2020-11-10 [patent_title] => Fused heterocyclic derivatives as S1P modulators [patent_app_type] => reissue [patent_app_number] => 16/261786 [patent_app_country] => US [patent_app_date] => 2019-01-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 24389 [patent_no_of_claims] => 38 [patent_no_of_ind_claims] => 12 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16261786 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16259237 [patent_doc_number] => RE048171 [patent_country] => US [patent_kind] => E1 [patent_issue_date] => 2020-08-25 [patent_title] => Substituted nucleosides, nucleotides and analogs thereof [patent_app_type] => reissue [patent_app_number] => 16/130971 [patent_app_country] => US [patent_app_date] => 2018-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 82377 [patent_no_of_claims] => 57 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16130971 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16182956 [patent_doc_number] => RE048105 [patent_country] => US [patent_kind] => E1 [patent_issue_date] => 2020-07-21 [patent_title] => Compounds for the treatment of mycobacterial infections [patent_app_type] => reissue [patent_app_number] => 16/103823 [patent_app_country] => US [patent_app_date] => 2018-08-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9415 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16103823 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16427603 [patent_doc_number] => RE048302 [patent_country] => US [patent_kind] => E1 [patent_issue_date] => 2020-11-10 [patent_title] => Embolic compositions [patent_app_type] => reissue [patent_app_number] => 16/045954 [patent_app_country] => US [patent_app_date] => 2018-07-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11028 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 155 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16045954 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15066917 [patent_doc_number] => RE047690 [patent_country] => US [patent_kind] => E1 [patent_issue_date] => 2019-11-05 [patent_title] => Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof [patent_app_type] => reissue [patent_app_number] => 15/968188 [patent_app_country] => US [patent_app_date] => 2018-05-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 20141 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => -36 [patent_words_short_claim] => 526 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15968188 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15480235 [patent_doc_number] => RE047848 [patent_country] => US [patent_kind] => E1 [patent_issue_date] => 2020-02-11 [patent_title] => Biheteroaryl compounds and uses thereof [patent_app_type] => reissue [patent_app_number] => 15/902746 [patent_app_country] => US [patent_app_date] => 2018-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31625 [patent_no_of_claims] => 53 [patent_no_of_ind_claims] => -1 [patent_words_short_claim] => 9 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15902746 [rel_patent_id] =>[rel_patent_doc_number] =>)